Please assess the completion status of the following clinical trial:

Trial Title: A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, aged 18-65 years old~* Prior endoscopic confirmation of UC:~Mildly to moderately active UC with Simple Clinical Colitis Activity Index (SCCAI) activity index \>4-9~* Failing standard therapy with:~stable doses of 5-ASA \>2 weeks; thiopurines \>3 months; or is steroid dependent at a dose \<20mg/d; (inability to taper off steroid for longer than 1 week)~* Stable medications dose for at least 2 weeks prior to screening and upon entry into trial~* Ability to understand and willingness to sign informed consent document~Exclusion Criteria:~* Diagnosis of Crohn's disease, indeterminate colitis, or proctitis alone~* Severe or fulminate colitis~* Women who are pregnant or nursing~* Patients who are unable to give informed consent~* Patients who are unable or unwilling to undergo colonoscopy~* Patients who have previously undergone FMT~* Patients who have a confirmed malignancy or cancer~* Patients who are immunocompromised~* Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab, certolizumab, natalizumab, thalidomide~* Antibiotic use within 2-months of start date~* Participation in a clinical trial in the preceding 30 days or simultaneously during this trial~* Probiotic use within 30 days of start date~* Rectal therapy within 14 days of start date~* Decompensated cirrhosis~* Congenital or acquired immunodeficiencies~* Other comorbidities including:~Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy~* Chronic kidney disease as defined by a GFR \<60mL/min/1.73m2 (40)~* History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia.~* Steroid \>20mg/day~* Positive screening and confirmatory tests for HIV 1 \& 2, Hepatitis A, B, \& C, and Syphilis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- fecal microbiota transplantation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).